Clinical trials: Advanced Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma, Kidney Cancer
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has the CAIX protein.
- Conditions
- Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
- Trial name
- NCT05239533
- Testing
- 177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
This study is being done in 2 parts. The first part is to determine the dose of RAD001 that should be used in combination with sorafenib.
- Trial name
- NCT00392821
- Testing
- Sorafenib, RAD001
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
This randomized phase III trial studies giving everolimus together with bevacizumab to see how well it works compared to everolimus alone in treating patients with advanced kidney cancer that progressed after first-line therapy.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01198158
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- 524 sites in United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Tumor, Advanced Solid Tumor
A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T
As a phase I clinical research，this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05468190
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma (RCC), Lung Cancer
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer
- Trial name
- NCT07181720
- Testing
- CD70-targeted CAR-T cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Clear Cell Renal Cell Carcinoma
Avelumab, Palbociclib and Axitinib in Advanced RCC
The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have…
- Trial name
- APART (NCT05176288)
- Testing
- Axitinib, Palbociclib, Avelumab
- Sponsor
- Bradley A. McGregor, MD
Carcinoma, Renal Cell
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
- Trial name
- NEXST (NCT01557127)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Poland
- Volunteers
- 205 people
- Sponsor
- Bayer
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney…
- Trial name
- NCT00403169
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07383441
- Testing
- Axitinib, Biospecimen Collection, Bone Scan
- Where
- 41 sites in United States
- Volunteers
- 718 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma, Renal Cell
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic…
- Trial name
- PISCES (NCT01064310)
- Testing
- pazopanib, sunitinib
- Where
- 51 sites in Finland, France and 3 more
- Volunteers
- 169 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
This is an open-label, single arm , Ib/II phase trial to evaluate the efficacy and safety of AK112（ivonescimab）monotherapy as first-line treatment for favourable risk advanced/metastatic renal cell carcinoma (a/m RCC).
- Trial name
- NCT06472895
- Testing
- AK112 monotherapy
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Metastatic Renal Cell Carcinoma
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
The clinical benefits of sunitinib and sorafenib have been demonstrated in patients with cytokine-refractory metastatic renal cell carcinoma.
- Trial name
- CROSS-J-RCC (NCT01481870)
- Testing
- Sorafenib-sunitinib, Sunitinib-sorafenib
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Yamagata University
Renal Cell Carcinoma
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer
This pilot research trial studies quantitative imaging metrics derived from contrast enhanced computed tomography (CECT) in enhancing assessment of disease status in patients with kidney cancer.
- Trial name
- NCT02370290
- Testing
- Medical Chart Review, Informational Intervention
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Southern California
Non-clear Cell Renal Cell Cancer
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
This will be a prospective, open-label, randomized multicenter phase-II study to evaluate progression free survival (PFS) in patients with locally advanced or metastatic non-clear cell renal cell cancer (ncc-RCC) receiving…
- Trial name
- NCT00979966
- Testing
- Temsirolimus, Sunitinib
- Where
- 14 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Central European Society for Anticancer Drug Research
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received…
- Trial name
- COMPARZ (NCT00720941)
- Testing
- Pazopanib, Sunitinib
- Where
- 227 sites in United States, Australia and 12 more
- Volunteers
- 1,110 people
- Sponsor
- Novartis Pharmaceuticals
Renal Cell Carcinoma
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™).
- Trial name
- NCT06234605
- Testing
- HC-7366, Belzutifan
- Where
- 21 sites in United States
- Volunteers
- 80 people
- Sponsor
- HiberCell, Inc.
Papillary Renal Cell Carcinoma
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
Multicenter, single arm, phase II study using a A'Hern single-stage procedure in patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) in first-line treatment.
- Trial name
- AXIPAP (NCT02489695)
- Testing
- Axitinib
- Where
- 10 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Leon Berard
Clear Cell Renal Cell Carcinoma
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
This is a phase II, open-label, multicenter, single-arm study evaluating the efficacy and safety of cadonilimab (AK104) in combination with lenvatinib in patients with unresectable advanced or metastatic clear cell renal cell…
- Trial name
- NCT06035224
- Testing
- AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
- Where
- China
- Volunteers
- 28 people
- Sponsor
- RenJi Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal cell carcinoma was conducted.Progression-free…
- Trial name
- SAARCC (NCT04958473)
- Testing
- Sintilimab, Axitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Second Hospital